...
首页> 外文期刊>The European journal of health economics: HEPAC : health economics in prevention and care >Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
【24h】

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation

机译:Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Electrical cardioversion (ECV) is a procedure in which a direct current electric shock is used to quickly and effectively restore the normal sinus rhythm. Appropriate anticoagulation reduces the risk of embolic events during and after ECV. The aim of this study was to estimate the cost-effectiveness of rivaroxaban compared with vitamin K oral antagonists (VKAs) in patients with atrial fibrillation undergoing elective ECV in the Netherlands.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号